Detalles de la búsqueda
1.
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
J Infect Dis
; 227(11): 1293-1302, 2023 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484484
2.
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Clin Infect Dis
; 70(10): 2073-2081, 2020 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31340042
3.
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
J Infect Dis
; 219(11): 1799-1803, 2019 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30715452
4.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Clin Immunol
; 169: 16-27, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27236001
5.
Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.
BMC Infect Dis
; 14: 425, 2014 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25078387
6.
Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine.
J Immunol
; 188(10): 5054-62, 2012 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22504653
7.
Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
Am J Respir Crit Care Med
; 188(4): 492-502, 2013 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23306546
8.
A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
J Clin Immunol
; 33(8): 1360-75, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24142232
9.
Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.
NPJ Vaccines
; 7(1): 132, 2022 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36316335
10.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Front Immunol
; 13: 852904, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35464450
11.
H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.
J Clin Immunol
; 31(3): 443-54, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21174144
12.
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.
Hum Vaccin
; 7(12): 1359-73, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22048172
13.
Whole blood can be used as an alternative to isolated peripheral blood mononuclear cells to measure in vitro specific T-cell responses in human samples.
J Immunol Methods
; 492: 112940, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33493551
14.
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.
Am J Trop Med Hyg
; 103(1): 132-141, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32342848
15.
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans.
Hum Vaccin
; 5(7): 475-82, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19587528
16.
Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
Hum Vaccin Immunother
; 15(9): 2090-2105, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30829100
17.
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
Vaccine
; 37(41): 6102-6111, 2019 09 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31447126
18.
Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine.
Hum Vaccin Immunother
; 14(1): 17-27, 2018 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28934066
19.
A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.
Medicine (Baltimore)
; 95(3): e2459, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26817879
20.
Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
Tuberculosis (Edinb)
; 100: 118-127, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27553419